Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma

Janos Szabó, Attila Végh, Gergo Rácz, B. Szende

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The antiandrogen and gonadotropin-releasing hormone (Gn-RH) analogue treatment of prostate carcinoma is based on decreased proliferative and increased apoptotic activity of tumor cells, induced by androgen ablation. Gn-RH analogues decrease the serum level of androgens by breaking the pituitary-gonadal axis, but increasing evidence points to the direct effect of Gn-RH analogues on tumor cells. Immunohistochemical demonstration of Gn-RH receptors recently became possible. Cryostat and paraffin sections of prostate biopsy samples of 10 untreated patients with prostate carcinoma (T2-T3, Gleason score 5-8) were investigated for Gn-RH receptors (Gn-RHR) and androgen receptors, respectively, using the immunoperoxidase method. Membrane bound, focal Gn-RHR positivity was found in 5 samples. Nuclear androgen receptor positivity appeared in 7 samples. No correlation between Gn-RHR and androgen receptor positivity was found, neither receptor status and tumor-nodes- metastasis stage nor Gleason score could be related to each other. Correlation between Gn-RHR positivity and response to luteinizing hormone-releasing hormone analogue treatment will be investigated further.

Original languageEnglish
Pages (from-to)399-401
Number of pages3
JournalUrologic Oncology: Seminars and Original Investigations
Volume23
Issue number6
DOIs
Publication statusPublished - Nov 2005

Fingerprint

LHRH Receptors
Gonadotropin-Releasing Hormone
Prostate
Carcinoma
Androgen Receptors
Neoplasm Grading
Androgens
Androgen Antagonists
Neoplasms
Cytoplasmic and Nuclear Receptors
Paraffin
Neoplasm Metastasis
Biopsy
Membranes
Therapeutics
Serum

Keywords

  • Carcinoma
  • Gonadotropin-releasing hormone receptor
  • Immunoperoxidase
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma. / Szabó, Janos; Végh, Attila; Rácz, Gergo; Szende, B.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 23, No. 6, 11.2005, p. 399-401.

Research output: Contribution to journalArticle

@article{f22b1fdec6f0487fbd6803bb1c6516c5,
title = "Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma",
abstract = "The antiandrogen and gonadotropin-releasing hormone (Gn-RH) analogue treatment of prostate carcinoma is based on decreased proliferative and increased apoptotic activity of tumor cells, induced by androgen ablation. Gn-RH analogues decrease the serum level of androgens by breaking the pituitary-gonadal axis, but increasing evidence points to the direct effect of Gn-RH analogues on tumor cells. Immunohistochemical demonstration of Gn-RH receptors recently became possible. Cryostat and paraffin sections of prostate biopsy samples of 10 untreated patients with prostate carcinoma (T2-T3, Gleason score 5-8) were investigated for Gn-RH receptors (Gn-RHR) and androgen receptors, respectively, using the immunoperoxidase method. Membrane bound, focal Gn-RHR positivity was found in 5 samples. Nuclear androgen receptor positivity appeared in 7 samples. No correlation between Gn-RHR and androgen receptor positivity was found, neither receptor status and tumor-nodes- metastasis stage nor Gleason score could be related to each other. Correlation between Gn-RHR positivity and response to luteinizing hormone-releasing hormone analogue treatment will be investigated further.",
keywords = "Carcinoma, Gonadotropin-releasing hormone receptor, Immunoperoxidase, Prostate",
author = "Janos Szab{\'o} and Attila V{\'e}gh and Gergo R{\'a}cz and B. Szende",
year = "2005",
month = "11",
doi = "10.1016/j.urolonc.2005.04.001",
language = "English",
volume = "23",
pages = "399--401",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma

AU - Szabó, Janos

AU - Végh, Attila

AU - Rácz, Gergo

AU - Szende, B.

PY - 2005/11

Y1 - 2005/11

N2 - The antiandrogen and gonadotropin-releasing hormone (Gn-RH) analogue treatment of prostate carcinoma is based on decreased proliferative and increased apoptotic activity of tumor cells, induced by androgen ablation. Gn-RH analogues decrease the serum level of androgens by breaking the pituitary-gonadal axis, but increasing evidence points to the direct effect of Gn-RH analogues on tumor cells. Immunohistochemical demonstration of Gn-RH receptors recently became possible. Cryostat and paraffin sections of prostate biopsy samples of 10 untreated patients with prostate carcinoma (T2-T3, Gleason score 5-8) were investigated for Gn-RH receptors (Gn-RHR) and androgen receptors, respectively, using the immunoperoxidase method. Membrane bound, focal Gn-RHR positivity was found in 5 samples. Nuclear androgen receptor positivity appeared in 7 samples. No correlation between Gn-RHR and androgen receptor positivity was found, neither receptor status and tumor-nodes- metastasis stage nor Gleason score could be related to each other. Correlation between Gn-RHR positivity and response to luteinizing hormone-releasing hormone analogue treatment will be investigated further.

AB - The antiandrogen and gonadotropin-releasing hormone (Gn-RH) analogue treatment of prostate carcinoma is based on decreased proliferative and increased apoptotic activity of tumor cells, induced by androgen ablation. Gn-RH analogues decrease the serum level of androgens by breaking the pituitary-gonadal axis, but increasing evidence points to the direct effect of Gn-RH analogues on tumor cells. Immunohistochemical demonstration of Gn-RH receptors recently became possible. Cryostat and paraffin sections of prostate biopsy samples of 10 untreated patients with prostate carcinoma (T2-T3, Gleason score 5-8) were investigated for Gn-RH receptors (Gn-RHR) and androgen receptors, respectively, using the immunoperoxidase method. Membrane bound, focal Gn-RHR positivity was found in 5 samples. Nuclear androgen receptor positivity appeared in 7 samples. No correlation between Gn-RHR and androgen receptor positivity was found, neither receptor status and tumor-nodes- metastasis stage nor Gleason score could be related to each other. Correlation between Gn-RHR positivity and response to luteinizing hormone-releasing hormone analogue treatment will be investigated further.

KW - Carcinoma

KW - Gonadotropin-releasing hormone receptor

KW - Immunoperoxidase

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=27844465409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844465409&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2005.04.001

DO - 10.1016/j.urolonc.2005.04.001

M3 - Article

VL - 23

SP - 399

EP - 401

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 6

ER -